Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Total Assets
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A total assets. Based on the latest financial reports, Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) holds total assets worth CN¥6.02 Billion CNY (≈ $880.77 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see 002932 company net worth for the company's overall valuation and market capitalisation.
Total Assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
Total assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025. This chart illustrates how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's total assets have evolved over time, based on quarterly financial data. See Wuhan Easy Diagnosis Biomedicine Co Ltd (002932) share price today for real-time trading data and today's change.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Asset Composition Analysis
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Total Assets Breakdown (December 2025)
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A total assets breakdown as of December 2025. Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's total assets of CN¥6.02 Billion consist of 78.3% current assets and 21.7% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 8.5% |
| Accounts Receivable | CN¥466.40 Million | 7.8% |
| Inventory | CN¥65.10 Million | 1.1% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥26.54 Million | 0.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2011–2025)
This chart illustrates how Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 002932 net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's current assets represent 78.3% of total assets in 2025, an increase from 77.1% in 2011.
- Cash Position: Cash and equivalents constituted 8.5% of total assets in 2025, down from 32.1% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is accounts receivable at 7.8% of total assets.
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A Competitors by Total Assets
Key competitors of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Vitrolife AB
ST:VITR
|
Sweden | Skr11.30 Billion |
|
Sinocare Inc
SHE:300298
|
China | CN¥6.25 Billion |
|
Shanghai Sanyou Medical Co Ltd
SHG:688085
|
China | CN¥2.34 Billion |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Nanjing Vishee Medical Technology Co Ltd
SHG:688580
|
China | CN¥1.79 Billion |
|
TAIDOC TECHNOLOGY CORP
TW:4736
|
Taiwan | NT$13.07 Billion |
|
SS Innovations International Inc. Common Stock
NASDAQ:SSII
|
USA | $96.98 Million |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.35 | 10.22 | 7.05 |
| Quick Ratio | 17.98 | 10.04 | 6.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.44 Billion | CN¥3.89 Billion | CN¥1.51 Billion |
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A - Advanced Valuation Insights
This section examines the relationship between Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.72 |
| Latest Market Cap to Assets Ratio | 0.08 |
| Asset Growth Rate (YoY) | -9.3% |
| Total Assets | CN¥5.98 Billion |
| Market Capitalization | $494.04 Million USD |
Valuation Analysis
Below Book Valuation: The market values Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's assets below their book value (0.08x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Wuhan Easy Diagnosis Biomedicine Co Ltd Class A's assets decreased by 9.3% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (2011–2025)
The table below shows the annual total assets of Wuhan Easy Diagnosis Biomedicine Co Ltd Class A from 2011 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥5.98 Billion ≈ $875.11 Million |
-9.29% |
| 2024-12-31 | CN¥6.59 Billion ≈ $964.77 Million |
-10.74% |
| 2023-12-31 | CN¥7.39 Billion ≈ $1.08 Billion |
-19.63% |
| 2022-12-31 | CN¥9.19 Billion ≈ $1.34 Billion |
+168.97% |
| 2021-12-31 | CN¥3.42 Billion ≈ $500.03 Million |
+139.52% |
| 2020-12-31 | CN¥1.43 Billion ≈ $208.76 Million |
+123.46% |
| 2019-12-31 | CN¥638.42 Million ≈ $93.42 Million |
+3.45% |
| 2018-12-31 | CN¥617.15 Million ≈ $90.31 Million |
+140.57% |
| 2017-12-31 | CN¥256.54 Million ≈ $37.54 Million |
+30.13% |
| 2016-12-31 | CN¥197.15 Million ≈ $28.85 Million |
+47.17% |
| 2015-12-31 | CN¥133.96 Million ≈ $19.60 Million |
+119.56% |
| 2014-12-31 | CN¥61.01 Million ≈ $8.93 Million |
+156.45% |
| 2013-12-31 | CN¥23.79 Million ≈ $3.48 Million |
+410.85% |
| 2012-12-31 | CN¥4.66 Million ≈ $681.46K |
+137.91% |
| 2011-12-31 | CN¥1.96 Million ≈ $286.44K |
-- |
About Wuhan Easy Diagnosis Biomedicine Co Ltd Class A
Wuhan Easy Diagnosis Biomedicine Co.,Ltd. engages in the research and development, production, and sale of vitro diagnostic reagents and diagnostic instruments in China. The company offers external diagnostic testing, third-party medical testing, certification consulting services, and medical information platform construction services. It also provides information software and supporting hardware… Read more